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TM6SF2 rs58542926 influences hepatic fibrosis
progression in patients with non-alcoholic fatty
liver disease
Yang-Lin Liu1, Helen L. Reeves2, Alastair D. Burt1,w, Dina Tiniakos1, Stuart McPherson1, Julian B.S. Leathart1,
Michael E.D. Allison3, Graeme J. Alexander3, Anne-Christine Piguet4, Rodolphe Anty1,5, Peter Donaldson1,
Guruprasad P. Aithal6, Sven Francque7, Luc Van Gaal7, Karine Clement8, Vlad Ratziu8, Jean-Francois Dufour4,
Christopher P. Day1, Ann K. Daly1,* & Quentin M. Anstee1,*
Non-alcoholic fatty liver disease (NAFLD) is an increasingly common condition, strongly
associated with the metabolic syndrome, that can lead to progressive hepatic fibrosis,
cirrhosis and hepatic failure. Subtle inter-patient genetic variation and environmental factors
combine to determine variation in disease progression. A common non-synonymous poly-
morphism in TM6SF2 (rs58542926 c.449 C4T, p.Glu167Lys) was recently associated with
increased hepatic triglyceride content, but whether this variant promotes clinically relevant
hepatic fibrosis is unknown. Here we confirm that TM6SF2 minor allele carriage is associated
with NAFLD and is causally related to a previously reported chromosome 19 GWAS signal
that was ascribed to the gene NCAN. Furthermore, using two histologically characterized
cohorts encompassing steatosis, steatohepatitis, fibrosis and cirrhosis (combined n¼ 1,074),
we demonstrate a new association, independent of potential confounding factors (age, BMI,
type 2 diabetes mellitus and PNPLA3 rs738409 genotype), with advanced hepatic
fibrosis/cirrhosis. These findings establish new and important clinical relevance to TM6SF2 in
NAFLD.
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on-alcoholic fatty liver disease (NAFLD) represents a
spectrum of progressive liver disease characterized by
increased hepatic triglyceride content (HTGC) in the
absence of excess alcohol consumption1. NAFLD includes simple
steatosis, non-alcoholic steatohepatitis, fibrosis and ultimately
cirrhosis, and is strongly associated with features of the metabolic
syndrome (obesity, insulin resistance/type 2 diabetes mellitus
(T2DM) and dyslipidaemia)1. Reflecting the increasing
prevalence of these conditions, NAFLD is estimated to affect
approximately one-third of the population in many developed
countries. Simple steatosis is generally considered to have a
benign course and therefore to be of limited prognostic
relevance2,3. However, some NAFLD patients exhibit
progressive steatohepatitis leading to cirrhosis and/or
hepatocellular carcinoma (HCC), conditions that confer
increased morbidity and mortality1,4. Despite its high
prevalence, only a minority of NAFLD patients progress to
significant fibrosis and experience the associated morbidity1.
Thus, similar to other common diseases (for example, obesity,
T2DM and cardiovascular disease), NAFLD is best considered as
a complex trait in which disease phenotype results from
environmental exposures acting on a susceptible polygenic
background that comprises multiple independent modifiers5–7.
Genome-wide association studies (GWAS)8–10 and candidate-
gene studies11–15 have contributed greatly to our understanding
of the genetic contribution to NAFLD pathogenesis and
variability of prognosis (reviewed in ref. 7). Among the loci
identified, the non-synonymous single-nucleotide polymorphism
(SNP) in PNPLA3 (rs738409 c.444 C4G, p.Ile148Met), patatin-
like phospholipase domain containing 3, has been validated across
multiple patient cohorts8,9,12,16. Importantly, carriage of this SNP
has been robustly associated not only with steatosis but also with
clinically relevant factors, including severity of hepatic fibrosis/
cirrhosis and development of NAFLD-related HCC12,17,18.
Recently, Kozlitina et al.19 showed that a non-synonymous
SNP in TM6SF2 (rs58542926 c.449 C4T, p.Glu167Lys),
transmembrane 6 superfamily member 2, a gene of unknown
function on chromosome 19, was associated with proton
magnetic resonance spectroscopy (1H-MRS) quantified HTGC
based on genotyping with a genome-wide exome chip19. This
variant has also been associated with dyslipidaemia and
cardiovascular risk20. The TM6SF2 rs58542926 SNP lies within
50 kb of an NCAN gene variant (rs2228603 c.274 C4T,
p.Pro92Ser) that has previously been associated with HTGC in
another GWAS9,21. Both SNPs are in strong linkage
disequilibrium (D0¼ 0.926, r2¼ 0.798). Conditioning on the
TM6SF2 variant abrogated the effect of the NCAN variant while
the reverse did not occur, suggesting that TM6SF2 rs58542926 is
more strongly associated with the HTGC phenotype.
Homozygote TM6SF2 rs58542926 minor (T) allele carriage was
shown to be associated with a modest but statistically significant
increase in 1H-MRS measured HTGC from 5.86±0.25% in CC
homozygotes to 15.04±2.23% in TT homozygotes19. In vitro and
in vivo functional studies also supported this conclusion but were
unable to determine whether the effect of TM6SF2 was limited to
steatosis or had broader clinical relevance, as has already been
shown for PNPLA3 (ref. 19).
The aim of the current study was, first, to determine whether
the association with NAFLD reported by Kozlitina et al.19 could
be independently validated; and, second, to establish whether
the TM6SF2 rs58542926 variant was associated with clinically
important disease end points that have prognostic relevance (in
particular stage of hepatic fibrosis or development of NAFLD-
related HCC). To address this, we perform a quantitative analysis
within a well-characterized European Caucasian ‘discovery’
cohort with histologically characterized NAFLD, controlling for
relevant co-morbidities and factors that have previously been
linked with disease progression (age, gender, body mass index
(BMI), presence of T2DM and PNPLA3 rs738409 genotype), and
replicate our findings in a separate histologically characterized
European Caucasian ‘validation’ cohort. To discover whether the
TM6SF2 rs58542926 variant also confers an increased risk of
NAFLD-related HCC, we perform a secondary case–control
analysis comparing the overall ‘combined’ cohort of NAFLD
patients to a cohort of NAFLD–HCC patients.
Results
Increased TM6SF2 rs58542926 C4T minor allele carriage
in NAFLD. In the NAFLD discovery cohort, the TM6SF2
rs58542926 genotypes were confirmed to be in Hardy–Weinberg
equilibrium with a minor allele frequency of 0.12, significantly
higher than that observed in a reference Northern European
population sample (MAF 0.07, http://browser.1000genomes.org)
or a cohort of 265 Caucasian self-reported ‘healthy workers’
recruited from offices and factories locally in the North East of
England (MAF 0.07) and so supportive of an association between
these variants and NAFLD. Indeed, a gene-dosage effect was
observed for both variants in the discovery cohort with the
incidence of NAFLD increasing with the number of minor alleles
possessed (X2 for trend, P¼ 0.0008; Supplementary Table 1).
A similar association was also confirmed for PNPLA3 rs738409,
P¼ 0.0001 (Supplementary Table 2). Specific histological com-
ponents of the NAFLD disease phenotype were next assessed
individually.
TM6SF2 and degree of histological steatosis. As a positive
control, and consistent with our previously reported analysis12,
carriage of the PNPLA3 rs738409 minor allele was significantly
associated with degree of steatosis in multivariate analysis
adopting an additive model adjusted for gender, age at biopsy,
BMI and presence of T2DM (b¼ 0.192±0.056, 95% confidence
interval (CI) 0.082–0.301; P¼ 6.74 10ÿ 4). However, in contrast
to the report by Kozlitina et al.19, neither TM6SF2 rs58542926
(b¼ 0.087±0.083, 95%CI ÿ 0.076 to 0.250; P¼ 0.296) nor
NCAN rs2228603 (b¼ 0.050±0.085, 95%CI ÿ 0.116 to 0.216;
P¼ 0.554) were found to be significantly associated with degree of
histologically determined steatosis in the 349-patient discovery
cohort. This was also the case in the 725-patient validation cohort
(P¼ 0.17). However, a trend towards significance was observed
when the two cohorts were combined (b¼ 0.111±0.059, 95%CI
ÿ 0.0041 to 0.2268; P¼ 0.053), suggesting that an underlying
effect on degree of steatosis may be present but of relatively small
size. An effect became apparent when the multivariate analysis in
the combined cohort was repeated after subdividing the cohort
into those with mild steatosis (S0–1) and pronounced steatosis
(S2–3). Here, carriage of each copy of the TM6SF2 rs58542926
C4T minor allele was associated with increased risk of greater
steatosis (odds ratio (OR) 1.379, 95%CI 1.019–1.865; P¼ 0.037),
although with a marginal level of significance.
TM6SF2 and severity of histological steatohepatitis. Next, the
association with steatohepatitis activity was tested using a com-
posite score incorporating severity of necroinflammation and
ballooning hepatocyte degeneration. TM6SF2 rs58542926, but not
NCAN rs2228603, was associated with severity of steatohepatitis
in the discovery cohort by multivariate analysis adopting an
additive model adjusted for gender, age at biopsy, BMI, T2DM
and PNPLA3 rs738409 genotype (b¼ 0.288±0.139, 95%CI
0.015–0.561; P¼ 0.039). However, this effect was not replicated in
the validation or combined cohorts.
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TM6SF2 and stage of histological fibrosis. Finally, the associa-
tion with NAFLD fibrosis stage was tested. In the discovery
cohort multivariate analyses adopting an additive model adjusted
for gender, age at biopsy, BMI, T2DM and PNPLA3 rs738409
genotype found that TM6SF2 rs58542926 (b¼ 0.549±0.135,
95%CI 0.285–0.813; P¼ 5.57 10ÿ 5) and NCAN rs2228603
(b¼ 0.419±0.138, 95%CI 0.148–0.689; P¼ 0.0026) were both
significantly associated with stage of fibrosis. The association
between TM6SF2 rs58542926 and fibrosis stage persisted
when analysis included both the NCAN rs2228603 and the
PNPLA3 rs738409 SNPs as covariates (b¼ 0.552±0.205, 95%CI
0.151–0.953; P¼ 0.0074). However, the association with NCAN
rs2228603 was lost when the analysis was conditioned on
rs58542926. Thus, the association is driven by the TM6SF2
rs58542926 variant, and carriage of its minor allele confers sig-
nificantly greater NAFLD-related hepatic fibrosis independent of
gender, age at biopsy, BMI, T2DM and PNPLA3 rs738409
genotype.
This strong association between TM6SF2 rs58542926 and
fibrosis stage was replicated independently in the validation
cohort (b¼ 0.238±0.097, 95%CI 0.047–0.428; P¼ 0.014)
and also clearly demonstrated in the combined cohort
(b¼ 0.357±0.079, 95%CI 0.203–0.511; P¼ 6.36 10ÿ 6) by
using an additive model adjusted for gender, age at biopsy,
BMI, T2DM and PNPLA3 rs738409 genotype in both cases. To
illustrate the potential clinical relevance of this finding, when the
multivariate analysis was repeated subdividing the NAFLD cohort
into those with mild fibrosis (F0–1) and advanced fibrosis (F2–4),
carriage of each copy of the TM6SF2 rs58542926 C4T minor
allele was associated consistently with a significant increased risk
of advanced fibrosis, independent of gender, age at biopsy, BMI,
T2DM and PNPLA3 rs738409 genotype across each cohort
studied (Table 1).
TM6SF2 and risk of HCC. There is increasing evidence that
NAFLD predisposes to an increased risk of HCC22, an effect
influenced by PNPLA3 rs738409 genotype independent of the
presence of cirrhosis18. We therefore sought to determine
whether TM6SF2 rs58542926 had a similar effect. A cohort of
99 consecutive Northern European Caucasian patients with
primary NAFLD-related HCC was identified according to the
joint European Association for the Study of the Liver and
European Association for the Research and Treatment of Cancer
(EASL-EORTC) guidelines23. TM6SF2 rs58542926 allele and
genotype frequencies in this cohort were compared with the
combined NAFLD cohort described above (n¼ 1,074). In
univariate analysis, homozygote carriage of the TM6SF2
rs58542926 minor allele was associated with an increased risk
of NAFLD–HCC with respect to CC (OR 1.922, 95%CI 1.31–2.81;
P¼ 6.81 10ÿ 4); however, significance was lost in multivariate
analysis incorporating known risk factors including age, gender,
BMI, T2DM and presence of cirrhosis (P¼ 0.42).
Discussion
The region on chromosome 19 (19p13) flanking TM6SF2 has
been reported to be associated with NAFLD9,19,21 as well as
variations in plasma cholesterol, triglyceride and low-density
lipoprotein levels20,24,25 in several previous studies. In particular,
a variant within the NCAN gene (rs2228603 C4T) that is in
strong linkage disequilibrium (D0¼ 0.926, r2¼ 0.798) with
TM6SF2 rs58542926 was reported to be associated with
radiologically and histologically characterized NAFLD in both
GWAS and candidate-gene studies9,21. Before the recent
publication by Kozlitina et al.19, examination of linkage
disequilibrium patterns across the region had already brought
that association into question7. It was, however, the use of a
genome-wide exome-chip genotyping approach, combined with
detailed association analysis conditioning on previously published
variants across the 19p13 region, that determined that the
causative variant affecting HTGC was TM6SF2 rs58542926
(ref. 19). When considered alongside a separate study by
Holmen et al.20, which demonstrated an association with
cardiovascular disease and circulating triglyceride/total
cholesterol levels, it appears that TM6SF2 rs58542926 C-allele
carriage increases circulating triglyceride/total cholesterol while
T-allele carriage promotes hepatic triglyceride/cholesterol
retention. In clinical practice, simple steatosis is generally
considered to have a benign course and so degree of HTGC is
of limited prognostic relevance1,3,26. In contrast, progressive
hepatic fibrosis leading to cirrhosis is the principal common
pathway to hepatic failure and a liver-related death2,3. Using
two large, well-characterized European Caucasian cohorts with
biopsy-proven NAFLD, we demonstrate that carriage of the
TM6SF2 rs58542926 variant is strongly associated with the
presence of NAFLD and, in particular, with a significantly greater
risk of developing advanced hepatic fibrosis/cirrhosis.
Evidence to support a modifier effect of the TM6SF2
rs58542926 variant on histologically determined HTGC
(steatosis), seen only when the 1,074-patient strong combined
cohort was studied, is arguably more modest than might be
expected. Our findings do support the previously reported
association9,19,21, although differences in sensitivity to subtle
changes in HTGC between radiological and histological
modalities may have reduced the power to detect this effect27.
Kozlitina et al.19 reported that the maximal effect of the TM6SF2
variant in European Caucasians was only a mean 9.2% increase in
1H-MRS quantified HTGC in TT homozygotes above theB5.9%
observed in CC homozygotes19. Histological assessment of
hepatic steatosis uses broad microscopic categories reflecting
Table 1 | Multivariate analysis of association between TM6SF2 rs58542926 genotype and fibrosis stage F0–1 (mild) versus F2–4
(advanced).
Variables Discovery cohort (n¼ 349) Validation cohort (n¼ 725) Combined cohort (n¼ 1,074)
OR (95%CI) P-value OR (95%CI) P-value OR (95%CI) P-value
TM6SF2 genotype 2.94 (1.76–4.89) 3.44 10ÿ 5 1.46 (1.03–2.09) 0.0362 1.88 (1.41–2.5) 1.63 10ÿ 5
PNPLA3 genotype 1.57 (1.21–2.19) 0.0086 1.32 (1.05–1.66) 0.0183 1.40 (1.16–1.69) 4.84 10ÿ4
Age 1.03 (1.01–1.06) 0.0045 1.02 (1.01–1.04) 0.0041 1.03 (1.01–1.04) 1.57 10ÿ 5
Gender (female) 0.94 (0.57–1.56) 0.8297 1.81 (1.30–2.50) 4.50 10ÿ4 1.43 (1.09–1.89) 0.0096
BMI 1.05 (1.00–1.10) 0.0368 1.03 (1.01–1.05) 9.80 10ÿ4 1.04 (1.02–1.05) 3.78 10ÿ 5
T2DM 2.39 (1.49–3.84) 0.0003 2.73 (1.93–3.88) 1.68 10ÿ8 2.57 (1.95–3.39) 1.78 10ÿ 11
BMI, body mass index; CI, confidence interval; OR, odds ratio; T2DM, type 2 diabetes mellitus.
Additive model including age, gender, BMI, T2DM and PNPLA3 rs738409 genotype as covariates. Discovery/validation/combined cohorts: stage F0–1 (mild) n¼ 198/439/637, stage F2–4 (advanced)
n¼ 151/286/437.
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the proportion of hepatocytes that are visibly steatotic (S0 o5%,
S1 5–33%, S2 33–66% and S3 466%)28. Based on data from
previous comparative modality analysis27, the modest gene effect
size reported by Kozlitina et al.19 (less than a threefold increase in
HTGC above normal) would likely be encompassed within the
histological S1 bracket, and therefore may not be apparent
histologically. Combined with the relatively low minor allele
frequency in the background population, smaller cohorts may
therefore have insufficient statistical power for an association to
become evident.
The modifier effect of the TM6SF2 variant on grade of
steatohepatitis (disease activity) was apparent in the initial
discovery cohort analysis; however, statistical significance was
not reached in the subsequent validation analysis. The validation
cohort comprised a mixture of patients recruited from
both hepatology and bariatric services and, although the
cohorts appear well matched histologically, the validation
cohort exhibited higher mean BMI levels (38.5±9.1 versus
34.5±5.7 kgmÿ 2, Po0.0001), a younger mean age (47.6±12.4
versus 51.5±12.0 years, Po0.0001), a greater female preponder-
ance (56.1 versus 32.1%, Po0.0001) and a lower prevalence of
T2DM (32.4 versus 46.1%, Po0.0001) than the discovery cohort
(Table 2). These factors may have impacted on our ability to
replicate the initial association with steatohepatitis in a multi-
variate analysis. Further study of the variant in other patient
cohorts and exploration of the functional effects of TM6SF2 on
inflammatory response will be needed to address this point.
The key finding of the current study is that carriage of the
TM6SF2 rs58542926 C4T minor allele is unequivocally asso-
ciated with an increased risk of advanced NAFLD-associated
hepatic fibrosis. This highly significant effect was consistently
demonstrated across all the cohorts studied and was independent
of potentially confounding factors including gender, age at time
of biopsy, BMI, T2DM and PNPLA3 rs738409 genotype.
Conditional analysis undertaken as part of the present study
adds further weight to the assertion that the 19p13 signal is
causally related to TM6SF2 and not NCAN, not only for HTGC as
was previously reported19 but now also for stage of hepatic
fibrosis. These findings therefore establish a new and important
clinical relevance to the recently described association between
TM6SF2 and NAFLD, and suggest that TM6SF2 should be
considered alongside PNPLA3 (refs 8,12) and GCKR9,29,30, as one
of a handful of genes so far identified that are associated not only
with variations in hepatic triglyceride accumulation but also with
fibrogenesis7. It is noteworthy that across all the cohorts studied,
the OR for advanced fibrosis conferred by each copy of the
TM6SF2 variant carried was consistently of similar or up to
twofold greater magnitude than that which was observed, or has
previously been reported12,31, for the widely studied PNPLA3
rs738409 variant (Table 1).
Carriage of the TM6SF2 variant was associated with increased
risk of progression to NAFLD–HCC in univariate analysis. In
contrast to PNPLA3 (ref. 18), this effect was not sustained when
confounding factors including age, T2DM and presence of
underlying cirrhosis were included in the model. Carriage of
the TM6SF2 variant therefore does not appear to further increase
HCC risk independent of its effect on fibrosis stage. It should,
however, be noted that the NAFLD–HCC cohort contained only
99 patients and so, combined with a relatively modest TM6SF2
rs58542926 minor allele frequency, the current study had B70%
power to detect an effect if an additive genetic model and risk
similar to that seen for fibrosis is assumed (a¼ 0.05)32. An
association cannot therefore be completely excluded, but would
seem unlikely. Studies using larger cohorts of NAFLD–HCC
patients than are presently available will be required to provide
sufficient power to study this further.
The TM6SF2 rs58542926 c.449 C4T variant is a non-
synonymous change producing a glutamate to lysine amino-acid
Table 2 | Demographic characteristics of patient cohorts.
Discovery cohort Validation cohort Combined cohort NAFLD–HCC cohort
Number 349 725 1,074 99
Ethnicity European Caucasian European Caucasian European Caucasian European Caucasian
Gender (female) 147 (42.1%) 407 (56.1%) 554 (51.6%) 19 (19.2%)
Age, years 51.5±12.0 47.6±12.4 48.9±12.4 70.5±8.0
BMI, kgmÿ 2 34.5±5.7 38.5±9.1 37.2±8.3 31.9±6.7
T2DM (yes) 161 (46.1%) 235 (32.4%) 396 (36.9%) 68 (68.7%)
Steatosis score*
S0 5 (1.4%) 60 (8.3%) 65 (6.1%) —
S1 99 (28.4%) 206 (28.4%) 305 (28.4%) —
S2 166 (47.6%) 247 (34.1%) 413 (38.5%) —
S3 79 (22.6%) 204 (28.1%) 283 (26.4%) —
Activity score (composite hepatocyte ballooning and necroinflammation scores)*
A0 81 (23.2%) 132 (18.2%) 213 (19.8%) —
A1 65 (18.6%) 133 (18.3%) 198 (18.4%) —
A2 101 (28.9%) 214 (29.5%) 315 (29.3%) —
A3 64 (18.3%) 149 (20.6%) 213 (19.8%) —
A4 31 (8.9%) 89 (12.3%) 120 (11.2%) —
Fibrosis score
F0 108 (30.9%) 277 (38.2%) 385 (35.8%)
F1 90 (25.8%) 162 (22.3%) 252 (23.5%) Non-cirrhotic: 32 (32.3%)
F2 55 (15.8%) 161 (22.2%) 216 (20.1%)
F3 66 (18.9%) 75 (10.3%) 141 (13.1%)
F4 (cirrhosis) 30 (8.6%) 50 (6.9%) 80 (7.4%) Cirrhotic: 67 (67.7%)
BMI, body mass index; HCC, hepatocellular carcinoma; NAFLD, non-alcoholic fatty liver disease; T2DM, type 2 diabetes mellitus.
*Steatosis and activity score data incomplete in 8 (0.7%) and 15 (1.3%) of samples, respectively.
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substitution at residue 167 (Glu167Lys), which is highly
conserved across mammals19. First identified as part of a
large-scale sequencing project, little is currently known about
the biological function of the TM6SF2 protein product33.
Adenovirus-mediated short hairpin RNA knockdown of Tm6sf2
in mice has been shown to increase HTGC and reduce very low-
density lipoprotein (VLDL) secretion, suggesting that TM6SF2
activity is necessary for normal VLDL secretion, and that
impaired TM6SF2 function causally contributes to NAFLD19.
However, these in vivo studies were of too short a duration to
adequately address the effects on steatohepatitis or fibrogenesis.
Furthermore, previous experimental evidence has shown that
hepatic triglyceride accumulation may not itself be directly
hepatotoxic. This was elegantly demonstrated in mice by silencing
hepatic gene expression of diacylglycerol O-acyltransferase 2
(Dgat2), a key enzyme mediating the conversion of free fatty acids
to triglyceride34. Rather than ameliorating steatohepatitis, the
consequent reduction in hepatocyte triglyceride synthesis was
associated with increased fatty acid oxidation, particularly
through Cyp2e1, leading to greater oxidative stress, cellular
damage and higher serum transaminase levels34. It is therefore
tempting to speculate that the function of TM6SF2 and the
mechanism through which TM6SF2 drives NAFLD-associated
hepatic fibrosis may be other than through increased triglyceride
accumulation.
In conclusion, the current study confirms that TM6SF2 is
associated with histologically defined NAFLD, and is the first
demonstration that this gene serves as a powerful modifier of
hepatic fibrogenesis. That this gene is also associated with disturbed
cholesterol metabolism and so may modify risk of cardiovascular
events including myocardial infarction20 suggests that TM6SF2 is
an important determinant of clinical outcome across several facets
of metabolic syndrome-related end-organ damage. In light of
evidence that cholesterol accumulation in hepatic stellate cells
promotes NAFLD fibrosis35, it is tempting to speculate that
TM6SF2 may act as a ‘switch’ with TM6SF2 rs58542926 T-allele-
mediated hepatic retention of triglyceride and cholesterol
predisposing to NAFLD fibrosis while C-allele carriage promotes
VLDL excretion, protecting the liver at the expense of increased risk
of cardiovascular disease. These data mandate further mechanistic
study to determine the physiological and pathophysiological role of
this gene in various tissues and cell types as a modifier of
fibrogenesis and a putative therapeutic target.
Methods
Patients. Patients were recruited from hepatology clinics at several European
specialist centres: the Freeman Hospital, Newcastle upon Tyne, UK; Addenbrooke’s
Hospital, Cambridge, UK; Nottingham University Hospitals NHS Trust,
Nottingham, UK; Inselspital Hospital, Bern, Switzerland; Antwerp University
Hospital, Belgium; and Pitie´-Salpeˆtrie`re Hospital, Paris, France. The study had
all the necessary ethical approvals (UK: Newcastle and North Tyneside 1 REC
(10/H0906/41), Norfolk REC (06/Q0106/70)] and Nottingham 2 REC
(GM010201); Switzerland: Inselspital Bern Local Ethics Committee; Belgium:
Antwerp University Hospital Ethics Committee; France: CPP (Comite´ de
Protection des Personnes) Paris VI IDF Pitie´—Salpeˆtrie`re Hospital). All
participants gave informed consent. In all cases, alternative diagnoses were
excluded, including excess alcohol intake (alcohol intakeo20 g per day for women;
and o30 g per day for men), chronic viral hepatitis (hepatitis B and hepatitis C),
autoimmune liver diseases, hereditary hemochromatosis, a1-antitrypsin deficiency,
Wilson’s disease and drug-induced liver injury. Clinical and laboratory data were
collected at the time of diagnosis including basic anthropometrics so that BMI
could be calculated, and relevant co-morbidity including the presence of T2DM
(fasting glucose Z7.1mmol lÿ 1 (Z128mg dlÿ 1) or treatment with anti-diabetic
drugs) and evidence of underlying cirrhosis was recorded. The degree of steatosis
(S0–3), activity of steatohepatitis (A0–4) and stage of fibrosis (F0–4) were
scored according to the validated semi-quantitative SAF score28. The main study
cohorts were:
 An initial discovery cohort of 349 consecutive European Caucasian patients from
the United Kingdom with histologically characterized NAFLD of different stages
of disease. These were unrelated patients with histologically characterized
NAFLD, derived from a patient population originally identified as having
ultrasonographically detected bright liver and abnormal biochemical tests
(alanine transaminase and/or gamma-glutamyl transferase).
 A validation cohort of 725 consecutive European Caucasian patients
from centres in UK and mainland Europe with histologically characterized
NAFLD of different stages of disease. Patients in this cohort were unrelated
patients with histologically characterized NAFLD, derived from a patient
population originally identified as having ultrasonographically detected bright
liver and abnormal biochemical tests (alanine transaminase and/or gamma-
glutamyl transferase) or identified as having evidence of NAFLD at the time
of bariatric surgery.
Together, these comprised the combined cohort of 1,074 patients with
histologically characterized NAFLD. Demographic and histological details are
shown in Table 2. A description of the ‘healthy workers’ cohort recruited in the
North East of the United Kingdom has previously been published36.
A separate cohort of 99 consecutive Northern European Caucasian patients
with primary HCC arising on a background of NAFLD was identified
(NAFLD–HCC cohort). The diagnosis of HCC was established histologically or
through non-invasive assessment according to the EASL–EORTC clinical practice
guidelines23. The presence of NAFLD was determined through histological
assessment of non-tumour liver tissue or, when biopsy was not clinically
appropriate, through radiological evidence of hepatic steatosis.
Liver biopsy. Liver biopsy was performed under radiological guidance. Specimens
(at least 1.6 cm length and 1.5mm thick) were fixed in 10% neutral formalin
for evaluation and embedded in paraffin for histological examination. Tissue sec-
tions were stained with haematoxylin and eosin, impregnated with silver for
visualizing reticulin framework and stained with Sirius Red Fast Green for visua-
lizing collagen. Liver biopsies were reviewed by a single expert liver pathologist at
each participating centre, unaware of clinical or genetic data. The degree of stea-
tosis (S0–3), activity of steatohepatitis (A0–4) and stage of fibrosis (F0–4) were
scored according to the validated semi-quantitative SAF score (Supplementary
Table 3)28,37. In 25 HCC patients, the diagnosis of HCC was confirmed
histologically and graded according to Edmondson and Steiner38, adapted for
needle biopsy specimens.
DNA preparation. Venous blood was collected from each patient and DNA was
prepared from peripheral blood lymphocytes using a perchlorate–chloroform
isolation method39. In brief, 35ml lysis buffer (10mM Tris–HCl (pH 8.0), 320mM
sucrose, 5mM magnesium chloride and 1% Triton X-100) was added to 5ml
venous blood in a 50-ml polypropylene centrifuge tube. After mixing, the tube was
centrifuged at 3,000 g for 10min. The supernatant was discarded and the cell pellet
was re-suspended in 2ml of solution B (400mM Tris–HCl (pH 8.0) 6 0mM EDTA,
150mM NaCl and 1% SDS). A quantity of 500 ml of sodium perchlorate (5M) was
added and the sample was mixed at room temperature for 15min before incubating
in a preheated hot block at 65 °C for 30min. Next, 2ml of chloroform was added
and the sample was mixed for 10min at room temperature. The tube was then
centrifuged at 1,400g for 10min, and the upper, clear DNA-containing phase was
transferred to a new 15ml polypropylene tube. Two volumes of cold ethanol were
added to the aqueous phase, and the tube was gently inverted until the DNA
precipitated. The DNA was spooled using a soft plastic sterile loop and allowed to
air dry for 20min. DNA was then re-suspended by incubation in 200 ml water at
60 °C. Samples are quantitated and quality assessed by absorbance measurements
at 260 and 280 nm. Genotyping was performed by personnel unaware of clinical
status or histology of patients.
TM6SF2 rs58542926, NCAN rs2228603 and PNPLA3 rs738409 genotyping.
TM6SF2 rs58542926, NCAN rs2228603 and PNPLA3 rs738409 genotypes were
determined by allelic discrimination using TaqMan reagents (Applied Biosystems
Inc., USA) according to the manufacturer’s protocol. Control samples of known
genotype were also included in every 96-well plate (blank, homozygous wild-type,
homozygous mutant and heterozygous).
Statistical analysis. Statistical analyses were performed using SPSS v19.0 (IBM,
USA) to collate and analyse cohort phenotype data. Continuous variables were
tested using Student’s t-test/one-way analysis of variance and categorical variables
by w2-squared test unless otherwise stated. PLINK v1.07 (ref. 40) (via the gPLINK
v2.050 GUI) was used to conduct the genetic analysis. An initial univariate
w2-squared analysis was performed. Subsequently, multivariate logistic regression
analysis was conducted incorporating biologically relevant covariates that were
associated with risk of NAFLD progression (age, gender, BMI, presence of
T2DM and PNPLA3 rs738409 genotype) to test the genetic association. An additive
genetic model best fitted the data and was reported. Results are expressed as beta
b±s.e.m. or OR with 95%CI as appropriate. Significance was taken as Po0.05
throughout.
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